scholarly journals SP374CANAGLIFLOZIN, A SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT-2) BLOCKER, NORMALIZES BLOOD GLUCOSE WITHOUT AFFECTING SYSTEMIC BLOOD PRESSURE, OXIDATIVE STRESS, INTRARENAL ANGIOTENSINOGEN GENE EXPRESSION AND KIDNEY INJURY IN TYPE 1 DIABETIC MICE

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i214-i214 ◽  
Author(s):  
John S.D. Chan ◽  
Isabelle Chenier ◽  
Anindya Ghosh ◽  
Chin-Han Wu ◽  
Chao-Sheng Lo ◽  
...  
2012 ◽  
Vol 251 (6) ◽  
pp. 1475-1481 ◽  
Author(s):  
Stefan Palkovits ◽  
Gabriele Fuchsjäger-Mayrl ◽  
Alexandra Kautzky-Willer ◽  
Sibylla Richter-Müksch ◽  
Ana Prinz ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Leena Mamilly ◽  
Lucy D. Mastrandrea ◽  
Claudia Mosquera Vasquez ◽  
Brett Klamer ◽  
Mahmoud Kallash ◽  
...  

BackgroundDiabetic nephropathy (DN) is one of the most common microvascular complications in type 1 diabetes Mellitus (T1D). Urinary markers of renal damage or oxidative stress may signal early stages of DN. The association of these markers with blood pressure (BP) patterns and glycemic variability (GV) in children is yet to be explored.MethodsSubjects between the ages of 10 and 21 years with T1D were enrolled. Continuous glucose monitoring (CGM) and ambulatory blood pressure monitoring (ABPM) were performed on each subject. Urine samples were collected and analyzed for albumin, creatinine, neutrophil gelatinase-associated lipocalin (NGAL) and pentosidine.ResultsThe study included 21 subjects (62% female) with median age of 16.8 (IQR: 14.5, 18.9). Median HbA1C was 8.4 (IQR: 7.5, 9.3). While microalbuminuria was negative in all but one case (4.8%), urinary NGAL/Cr and pentosidine/Cr ratios were significantly elevated (P<0.001) in diabetic patients despite having normal microalbuminuria, and they correlated significantly with level of microalbumin/Cr (r=0.56 [CI: 0.17, 0.8] and r=0.79 [CI: 0.54, 0.91], respectively). Using ABPM, none had hypertension, however, poor nocturnal systolic BP dipping was found in 48% of cases (95% CI: 28-68%). Urinary NGAL/Cr negatively correlated with nocturnal SBP dipping (r=-0.47, CI: -0.76, -0.03). Urine NGAL/Cr also showed a significant negative correlation with HbA1c measurements, mean blood glucose, and high blood glucose index (r=-0.51 [CI: -0.78, -0.09], r=-0.45 [CI: -0.74, -0.03], and r=-0.51 [CI: -0.77, -0.1], respectively). Median urinary NGAL/Cr and pentosidine/Cr ratios were higher in the high GV group but were not significantly different.DiscussionThis pilot study explores the role of ABPM and urinary markers of tubular health and oxidative stress in early detection of diabetic nephropathy. GV may play a role in the process of this diabetic complication.


Pharmacology ◽  
2018 ◽  
Vol 102 (3-4) ◽  
pp. 180-189 ◽  
Author(s):  
Debra Dorotea ◽  
Guideock Kwon ◽  
Jung Hwa Lee ◽  
Erika Saunders ◽  
Yun Soo Bae ◽  
...  

Background: NADPH oxidases (Nox) is a major enzyme system contributing to oxidative stress, which plays an important role in the pathogenesis of diabetic kidney disease (DKD). We have shown an elevation of renal Nox1, Nox2, and Nox4 in diabetic mice. APX-115, a pan-Nox inhibitor, attenuated the progression of DKD in mice. As the standard diabetic mice cannot fully mimic human DKD, the present study was aimed to show the dose-dependent effect and to provide a confirmatory evidence of APX-115 in attenuating DKD in diabetic rats. Method: Type 1 diabetes was induced by a single 60 mg/kg intraperitoneal injection of streptozotocin in Sprague-Dawley rats. 0.5, 5, or 30 mg APX-115/kg/day or losartan 1 mg/kg/day were administered orally to diabetic rats for 8 weeks. Results: APX-115 treatment showed an improvement in kidney function and tubular and podocyte ­injury, as well as attenuation of inflammation, fibrosis, and oxidative stress as much as losartan, a comparative drug and mainstay treatment in DKD. Therapeutic effect of APX-115 was exhibited in a dose-dependent manner; a dose of 30 mg/kg displayed a superior efficacy. Conclusion: This finding verified the pre-clinical data of APX-115 in protecting against DKD, which is important to bring APX-115 toward the next stage of drug development.


Sign in / Sign up

Export Citation Format

Share Document